Skin & hair

Where Light Therapy Fits in Eczema Care

Save

Creams and ointments are the backbone of eczema treatment, but when they stop being enough, phototherapy is often the next step before oral or injectable medication enters the conversation — not because it's a lesser option, but because it treats the skin directly with fewer systemic side effects. This article covers who phototherapy suits, what a typical course involves, and how the decision to escalate actually gets made.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

Where Phototherapy Sits on the Eczema Treatment Ladder

Eczema treatment typically starts with daily moisturizing and, during flares, a topical corticosteroid or a topical calcineurin inhibitor like tacrolimus — the first-line tier of eczema stepwise therapy, as detailed in AAD atopic dermatitis guideline recommendations for adults 1. Phototherapy sits a step above that: it's considered when topical treatment, used correctly and consistently, isn't controlling symptoms across enough of the body to be tolerable, but before committing to a systemic medication that affects the whole immune system rather than just the skin.

That middle position is deliberate. Phototherapy treats the skin directly with ultraviolet light rather than circulating through the bloodstream the way an oral or injectable medication does, which is part of why guidelines place it alongside — and sometimes ahead of — the newer systemic options for adults whose eczema has outgrown creams 2. Where exactly the switch happens differs from one clinician's practice to another, since guidelines describe a reasonable option rather than a strict sequence everyone follows the same way.

Who Tends to Be a Good Candidate

Phototherapy generally suits adults and older children with eczema that's spread across a meaningful portion of the body — too much surface area to treat practically with topical steroids alone — but who don't have the kind of severe, rapidly progressing disease that needs a faster-acting systemic option. It also suits people who'd rather avoid a medication that suppresses the immune system broadly, or who haven't responded adequately to a real trial of topical treatment.

The decision leans heavily on how much topical treatment has actually been tried, and for how long, before moving up a tier — a few days of inconsistent cream use isn't the same as a genuine trial, and clinicians generally want to see the latter before recommending phototherapy. Age also factors in loosely: phototherapy units are typically calibrated for older children and adults, and very young children are less often good candidates simply because standing still in a light-box for repeated sessions is impractical.

Why Not Skip Straight to a Biologic?

For eczema significant enough to need more than topicals, both phototherapy and systemic medications — including biologics like dupilumab, which has trial evidence showing meaningful improvement in itch, skin clearance, and quality of life for adults with moderate-to-severe disease 3 — are reasonable options, and guidelines don't rank one uniformly above the other 2. The tradeoff is more about lifestyle than effectiveness: phototherapy requires two to three in-person clinic visits a week for months, which is a real barrier for anyone without flexible time or nearby access to a phototherapy unit, while a biologic is typically a self-administered injection every few weeks with lab monitoring but far less travel.

For some people, avoiding a medication that affects the immune system broadly is worth the time commitment of phototherapy visits. For others, the opposite trade makes more sense. Neither is the objectively correct starting point — it depends on what's practical and what a particular person is trying to avoid.

What a Course of Phototherapy Actually Involves

A typical course means standing in a light-box style unit or, for smaller areas, a handheld device, for a treatment lasting seconds to a few minutes, several times a week, with the dose gradually increased over the first weeks as the skin adjusts. Most people see gradual improvement over six to twelve weeks rather than immediate relief, and maintaining that improvement usually means staying on a treatment schedule rather than stopping once symptoms calm down.

The mechanics of a single visit — how dosing decisions get made, what a light-box session feels like, and what side effects to expect — are covered in more detail inside a course of narrowband UVB; this section is only meant to convey the time commitment before deciding whether to start.

When Phototherapy Isn't the Right Fit

Phototherapy isn't suited to eczema that's acutely widespread or infected — active, weeping, infected eczema needs to be brought under control first, since UV light on a compromised skin barrier can worsen irritation before it helps. It's also a poor fit for anyone with a history of skin cancer, a condition that makes skin unusually sensitive to light, or who's taking a medication that increases photosensitivity, all of which raise the risk of UV exposure in ways a clinician needs to weigh individually.

Access is a practical barrier as much as a medical one: several visits a week for months isn't feasible for everyone's job, transportation, or location relative to a phototherapy unit, and that logistical reality is a legitimate reason to choose a systemic medication instead, not a lesser one. Pregnancy doesn't rule out phototherapy the way it complicates some systemic options, which is part of why it's sometimes preferred specifically for that reason rather than in spite of it.

How the Decision Actually Gets Made

Choosing between continuing topical treatment, starting phototherapy, or moving to a systemic medication is a conversation, not a formula — it weighs how much of the body is affected, how consistently topical treatment has actually been tried, how disruptive the eczema is to sleep and daily life, and what a particular person can realistically commit to logistically. Bringing a clear account of what's already been tried, for how long, and how well it worked helps that conversation move faster than starting from scratch at each visit.

It's also not a one-way door: some people cycle through a course of phototherapy, return to topical maintenance once skin clears, and revisit phototherapy or a systemic option again during a future flare, rather than picking one tier and staying on it permanently. For treatment-resistant eczema that doesn't respond adequately to either phototherapy or an initial systemic medication, further specialist evaluation figures into the plan rather than repeating the same step indefinitely.

Common questions

Most people see gradual improvement over six to twelve weeks of consistent treatment, not immediate relief after the first few sessions. Because the dose is increased slowly to avoid burning, the first couple of weeks are mostly about the skin adjusting rather than visible clearing.

They carry different risk profiles rather than one being uniformly safer. Phototherapy avoids a medication circulating through the whole body but adds cumulative UV exposure over time; a biologic works throughout the body but has strong trial evidence for effectiveness. Which tradeoff matters more is a personal decision made with a dermatologist.

Yes — phototherapy is often used alongside topical treatment rather than replacing it outright, especially during the transition while the light-box course builds toward its full effect. A dermatologist typically adjusts the topical regimen as phototherapy starts working rather than stopping creams abruptly.

If a full course of phototherapy — typically judged over two to three months — doesn't bring meaningful improvement, the next step is usually a systemic medication such as a biologic or an oral immunosuppressant, rather than extending phototherapy indefinitely at the same dose.

Coverage varies by plan, and many insurers require documentation that topical treatment was tried first and didn't work, which is part of why keeping a record of what's been used and for how long matters going into that first conversation with a dermatologist.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When to Ask About Escalating Beyond Creams

  • —eczema covering a large portion of the body despite consistent topical treatment
  • —skin that's weeping, crusted, or shows signs of infection rather than typical eczema
  • —sleep or daily function consistently disrupted by itching despite treatment
  • —a history of skin cancer or photosensitivity that needs to be weighed before starting light therapy

This article describes phototherapy in general terms; it can't determine whether phototherapy, a different treatment, or an urgent evaluation is right for a specific case of eczema — that decision is made with a clinician who can examine the skin directly.

References

  1. 1.Sidbury R, Alikhan A, Bercovitch L, et al. (2023). Guidelines of care for the management of atopic dermatitis in adults with topical therapies. Journal of the American Academy of Dermatology. doi:10.1016/j.jaad.2022.12.029AAD recommendations establishing moisturizers, topical corticosteroids, and topical calcineurin inhibitors as the first-line tier of adult atopic dermatitis treatment.
  2. 2.Sidbury R, Davis DM, Alikhan A, et al. (2024). Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. Journal of the American Academy of Dermatology. PMID 37943240AAD recommendations placing phototherapy and systemic therapy (biologics, JAK inhibitors, traditional immunosuppressants) as the tier above topical treatment for adults with moderate-to-severe atopic dermatitis.
  3. 3.Simpson EL, Bieber T, Guttman-Yassky E, et al. (2016). Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine. doi:10.1056/NEJMoa1610020 ✓SOLO 1 and SOLO 2 trial evidence that dupilumab improves itch, skin clearance, and quality of life in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy, used to illustrate the biologic alternative to phototherapy.

3 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library